RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study

Hyperkalemia is common in patients treated with renin–angiotensin–aldosterone system inhibitors (RAASis), and it represents the main cause of the large gap reported between guideline recommendations and real-world practice in chronic kidney disease (CKD). We conducted a CKD-population-based restrosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Eleonora, Capuano, Ivana, Buonanno, Pasquale, Andreucci, Michele, Provenzano, Michele, Amicone, Maria, Rizzo, Manuela, Pisani, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874323/
https://www.ncbi.nlm.nih.gov/pubmed/35224054
http://dx.doi.org/10.3389/fcvm.2022.824095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874323/
https://www.ncbi.nlm.nih.gov/pubmed/35224054
http://dx.doi.org/10.3389/fcvm.2022.824095

Ejemplares similares